Drug intelligence / Profile preview

ONO-8809

Development stage: Preclinical
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ONO-8809 is a thromboxane A2 receptor antagonist. It is being investigated for its potential to prevent chronic kidney disease (CKD) in hypertensive patients, particularly those with high salt intake. The drug has shown promise in reducing renal disorders by mitigating oxidative stress and thromboxane A2-induced effects in animal models.

Targets

TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on ONO-8809.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-8809.

Explore the full profile